• Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=15287027; PubMed=29970484).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=15287027; PubMed=29970484).
  

PubMed=8725545; DOI=10.3109/00016489609137854
Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.
Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma.
Acta Oto-Laryngol. 116:341-344(1996)

PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x
Servomaa K., Kiuru A., Grenman R., Pekkola-Heino K., Pulkkinen J.O., Rytomaa T.
p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines.
Cell Prolif. 29:219-230(1996)

PubMed=9187133
Soukka T., Salmi M., Joensuu H., Hakkinen L., Sointu P., Koulu L., Kalimo K., Klemi P., Grenman R., Jalkanen S.T.
Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.
Cancer Res. 57:2281-2289(1997)

PubMed=11799138; DOI=10.1177/002215540205000207
Eicheler W., Zips D., Dorfler A., Grenman R., Baumann M.
Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection.
J. Histochem. Cytochem. 50:197-204(2002)

PubMed=15287027; DOI=10.1002/gcc.20066
Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y., Grenman R., Fisher S.G., Carey T.E.
Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer.
Genes Chromosomes Cancer 41:145-154(2004)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733
Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A., Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M., Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.
Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.
Mol. Cancer Ther. 17:2060-2071(2018)

PubMed=30135316; DOI=10.1172/jci.insight.122204
Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A., Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D., Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M., Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R., Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J., McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G., Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
JCI Insight 3:e122204.1-e122204.19(2018)

DOI=10.1158/1538-7445.AM2020-507
Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J., Koritzinsky M., Wouters B.G.
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)